» Articles » PMID: 25928379

Identification of Sample-specific Regulations Using Integrative Network Level Analysis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2015 May 1
PMID 25928379
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Histologically similar tumors even from the same anatomical position may still show high variability at molecular level hindering analysis of genome-wide data. Leveling the analysis to a gene regulatory network instead of focusing on single genes has been suggested to overcome the heterogeneity issue although the majority of the network methods require large datasets. Network methods that are able to function at a single sample level are needed to overcome the heterogeneity and sample size issues.

Methods: We present a novel network method, Differentially Expressed Regulation Analysis (DERA) that integrates expression data to biological network information at a single sample level. The sample-specific networks are subsequently used to discover samples with similar molecular functions by identification of regulations that are shared between samples or are specific for a subgroup.

Results: We applied DERA to identify key regulations in triple negative breast cancer (TNBC), which is characterized by lack of estrogen receptor, progesterone receptor and HER2 expression and has poorer prognosis than the other breast cancer subtypes. DERA identified 110 core regulations consisting of 28 disconnected subnetworks for TNBC. These subnetworks are related to oncogenic activity, proliferation, cancer survival, invasiveness and metastasis. Our analysis further revealed 31 regulations specific for TNBC as compared to the other breast cancer subtypes and thus form a basis for understanding TNBC. We also applied DERA to high-grade serous ovarian cancer (HGS-OvCa) data and identified several common regulations between HGS-OvCa and TNBC. The performance of DERA was compared to two pathway analysis methods GSEA and SPIA and our results shows better reproducibility and higher sensitivity in a small sample set.

Conclusions: We present a novel method called DERA to identify subnetworks that are similarly active for a group of samples. DERA was applied to breast cancer and ovarian cancer data showing our method is able to identify reliable and potentially important regulations with high reproducibility. R package is available at http://csbi.ltdk.helsinki.fi/pub/czliu/DERA/.

Citing Articles

Inferring cell developmental stage-specific lncRNA regulation in the developing human neocortex with CDSlncR.

Huang M, Ma J, Zhang J Front Mol Neurosci. 2023; 15:1037565.

PMID: 36710930 PMC: 9880432. DOI: 10.3389/fnmol.2022.1037565.


Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders.

Truong T, Panizzutti B, Kim J, Walder K Pharmaceutics. 2022; 14(7).

PMID: 35890359 PMC: 9319329. DOI: 10.3390/pharmaceutics14071464.


Identification of Common Oncogenic Genes and Pathways Both in Osteosarcoma and Ewing's Sarcoma Using Bioinformatics Analysis.

Zhang J, Huang J, Liu W, Ding L, Cheng D, Xiao H J Immunol Res. 2022; 2022:3655908.

PMID: 35578666 PMC: 9107040. DOI: 10.1155/2022/3655908.


Estimating Sample-Specific Regulatory Networks.

Kuijjer M, Tung M, Yuan G, Quackenbush J, Glass K iScience. 2019; 14:226-240.

PMID: 30981959 PMC: 6463816. DOI: 10.1016/j.isci.2019.03.021.


Constructing tissue-specific transcriptional regulatory networks via a Markov random field.

Ma S, Jiang T, Jiang R BMC Genomics. 2019; 19(Suppl 10):884.

PMID: 30598101 PMC: 6311931. DOI: 10.1186/s12864-018-5277-6.


References
1.
Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M . Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature. 2006; 440(7084):702-6. DOI: 10.1038/nature04585. View

2.
Laakso M, Hautaniemi S . Integrative platform to translate gene sets to networks. Bioinformatics. 2010; 26(14):1802-3. DOI: 10.1093/bioinformatics/btq277. View

3.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

4.
Hollmen M, Maatta J, Bald L, Sliwkowski M, Elenius K . Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms. Oncogene. 2009; 28(10):1309-19. DOI: 10.1038/onc.2008.481. View

5.
Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View